Back to results
US 10,736,919 B2Granted
Materials and methods for engineering cells and uses thereof in immuno-oncology
AssigneeCrispr Therapeutics AG
InventorsJonathan Alexander Terrett, Demetrios Kalaitzidis, Lawrence Klein
Life of this patent
Estimating the term…
Abstract
Materials and methods for producing genome-edited cells engineered to express a chimeric antigen receptor (CAR) construct on the cell surface, and materials and methods for genome editing to modulate the expression, function, or activity of one or more immuno-oncology related genes in a cell, and materials and methods for treating a patient using the genome-edited engineered cells.
Claims11
A population of cells comprising engineered human T cells, wherein the engineered human T cells comprise:
- (a) a disrupted TRAC gene comprising a deletion of the nucleotide sequence of SEQ ID NO:
- 76;
- (b) a nucleic acid comprising a nucleotide sequence encoding a CAR, wherein the CAR comprises the amino acid sequence of SEQ ID NO:
- 1338, and wherein the nucleic acid is inserted in the disrupted TRAC gene;
- and
- (c) a disrupted B2M gene.
3 more elements
Dependencies are inferred from the claim text.